Tolterodine Tartrate interactions
Checked as Tolterodine in this data source.
Full monograph for Tolterodine TartrateCheck it against another medicine
Medicines
560 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Potassium Chloride | Major | Others | Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants… | 15 sources — open the full entry |
| Potassium Citrate | Major | Synergy | Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants… | 15 sources — open the full entry |
| Potassium Citrate + Citric Acid | Major | Synergy | Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants… | 15 sources — open the full entry |
| Sodium Chloride + Potassium Chloride + Sodium Acetate | Major | Others | Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants… | 15 sources — open the full entry |
| Topiramate | Major | Synergy | Certain drugs such as carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics… | 9 sources — open the full entry |
| Zonisamide | Major | Synergy | Certain drugs such as carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics… | 9 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumarate | Moderate | Synergy · Unknown | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary…2 documented mechanisms | 12 sources — open the full entry |
| Amantadine Hydrochloride | Moderate | Synergy | The anticholinergic-like adverse effects of amantadine may be potentiated by agents with anticholinergic properties such as antihistamines, antispasmodics… | 6 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Metabolism | Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the… | 2 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Absorption · Synergy · Unknown | Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta…2 documented mechanisms | 4 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the… | 2 sources — open the full entry |
| Aripiprazole | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Asciminib | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Asenapine Maleate | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Atenolol | Moderate | Absorption · Synergy | Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta… | 4 sources — open the full entry |
| Atenolol + Chlorthalidone | Moderate | Absorption · Synergy | Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta…2 documented mechanisms | 6 sources — open the full entry |
| Atropine Sulfate (Injection) | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrronium | Moderate | Synergy · Unknown | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…2 documented mechanisms | 19 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Metabolism · Unknown | Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the…3 documented mechanisms | 2 sources — open the full entry |
| Betamethasone + Clotrimazole | Moderate | Metabolism | Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the… | 2 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Moderate | Metabolism | Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the… | 2 sources — open the full entry |
| Betaxolol Hydrochloride | Moderate | Absorption · Synergy | Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta… | 4 sources — open the full entry |
| Bethanechol Chloride | Moderate | Antagonism | Anticholinergic agents and other agents with significant anticholinergic activity (e.g., clozapine, class IA antiarrhythmics especially disopyramide) may… | 2 sources — open the full entry |
| Bicalutamide | Moderate | Metabolism | Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the… | 2 sources — open the full entry |
| Bimatoprost + Timolol | Moderate | Absorption · Synergy · Unknown | Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta…2 documented mechanisms | 4 sources — open the full entry |
| Bisoprolol Fumarate | Moderate | Absorption · Synergy | Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta… | 4 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Moderate | Absorption · Synergy · Unknown | Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta…2 documented mechanisms | 4 sources — open the full entry |
| Bisoprolol Fumarate + Hydrochlorothiazide | Moderate | Absorption · Synergy | Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta…2 documented mechanisms | 6 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is… | 5 sources — open the full entry |
| Brexpiprazole | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Brigatinib | Moderate | Metabolism | Coadministration with brigatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Brigatinib has been shown in… | 6 sources — open the full entry |
| Brimonidine Tartrate + Timolol Maleate | Moderate | Absorption · Synergy · Unknown | Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta…2 documented mechanisms | 4 sources — open the full entry |
| Brinzolamide + Timolol | Moderate | Absorption · Synergy | Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta… | 4 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Synergy · Unknown | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…3 documented mechanisms | 19 sources — open the full entry |
| Carbidopa + LevodopaExtended releaseProlonged release | Moderate | Absorption | Anticholinergic agents may decrease the absorption and oral bioavailability of levodopa. The proposed mechanism involves increased gastrointestinal transit… | 10 sources — open the full entry |
| Cariprazine | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Carvedilol | Moderate | Absorption · Synergy | Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta… | 4 sources — open the full entry |
| Cenobamate | Moderate | Metabolism | Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is… | 1 sources — open the full entry |
| Ceritinib | Moderate | Metabolism | Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the… | 2 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Metabolism | Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the… | 2 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Metabolism · Unknown | Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the…2 documented mechanisms | 2 sources — open the full entry |
| Chlorpheniramine Maleate | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Chlorpromazine Hydrochloride | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| Cinnarizine + Dimenhydrinate | Moderate | Synergy | Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic… | 19 sources — open the full entry |
| CiprofloxacinbaseOphthalmic | Moderate | Metabolism | Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the… | 2 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Moderate | Metabolism · Unknown | Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the…2 documented mechanisms | 2 sources — open the full entry |
Food & lifestyle
alcohol
ModerateSynergy
Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous. In addition, the potential for abuse may be increased with the combination. The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.
What to do: Alcohol should generally be avoided during therapy with anticholinergic agents. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.
1 source
- Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12
Conditions
Conditions in which Tolterodine Tartrate needs care, as documented in this source.
Glaucoma, Angle-Closure
MajorThe use of tolterodine is contraindicated in patients with uncontrolled angle-closure (narrow angle) glaucoma. Tolterodine exerts anticholinergic activity and can result in increased intraocular pressure and loss of accommodation.
1 source
- "Product Information. Detrol (tolterodine)." Pharmacia and Upjohn (2001):
Intestinal Obstruction
MajorThe use of tolterodine is contraindicated in patients with GI obstruction, ileus, or obstructive uropathy. Tolterodine exerts anticholinergic activity by competitive antagonism of muscarinic receptors.
1 source
- "Product Information. Detrol (tolterodine)." Pharmacia and Upjohn (2001):
Central Nervous System Diseases
ModerateTolterodine is associated with anticholinergic central nervous system (CNS) effects. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered. Tolterodine should be used with caution in patients with Parkinson's disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.
1 source
- "Product Information. Detrol (tolterodine)." Pharmacia and Upjohn (2001):
Kidney Diseases
ModerateThe renal elimination of tolterodine and active metabolite is limited and a prolonged half-life is not anticipated in patients with renal impairment. However, the pharmacokinetic disposition of tolterodine has not been evaluated in patients with renal impairment and it is recommended that tolterodine be administered cautiously in patients with compromised renal function.
1 source
- "Product Information. Detrol (tolterodine)." Pharmacia and Upjohn (2001):
Liver Diseases
ModerateTolterodine undergoes biotransformation in the liver of extensive metabolizers to an active metabolite. Poor metabolizers have a greater concentration of active parent and less active metabolite, however the net activity of tolterodine is expected to be the same. The pharmacokinetic disposition of tolterodine can be significantly altered in patients with hepatic dysfunction. Therapy with tolterodine should be administered cautiously in patients with severe hepatic impairment and dosage should be reduced to no greater than 1 mg twice daily.
1 source
- "Product Information. Detrol (tolterodine)." Pharmacia and Upjohn (2001):
Long QT Syndrome
ModerateTolterodine has been associated with QT prolongation. The effect on QT interval correlates with plasma concentration of tolterodine. Caution is recommended when prescribing this agent to patients with a known history of QT prolongation or to patients who are taking Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications.
1 source
- "Product Information. Detrol (tolterodine)." Pharmacia and Upjohn (2001):
Myasthenia Gravis
ModerateTolterodine acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors. Caution is recommended when using this agent in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.
1 source
- "Product Information. Detrol (tolterodine)." Pharmacia and Upjohn (2001):
Therapeutic duplication
Drug classes that overlap with Tolterodine Tartrate, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Formoterol/glycopyrrolate
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Phenohytro
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Olodaterol/tiotropium
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Urolet mb
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Chlorpheniramine/methscopolamine/phenylephrine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Phosphasal
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Glycopyrrolate/indacaterol
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Sympak ii
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Motofen
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Librax
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Trelegy ellipta
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): B & o supprettes
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Butabarbital/hyoscyamine/phenazopyridine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Hyoscyamine/phenyltoloxamine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Duodote
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Duaklir pressair
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Tussigon
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Budesonide/formoterol/glycopyrrolate
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Albuterol/ipratropium
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Vi-atro
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Anoro ellipta
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Glycopyrrolate/neostigmine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Prosed ds